|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Long‐term outcome of hepatitis B virus‐related C hronic H epatitis under protracted nucleos(t)ide analogues显示文摘 | G. A. Niro A. M. Ippolito R. Fontana M. R. Valvano D. Gioffreda A. Iacobellis A. Merla M. Durazzo G. Lotti L. Di Mauro A. Andriulli | 2013 | J Viral Hepat2013，，7： | 3 |
| 2 | Risk of ventricular arrhythmia in patients with myocardial infarction and non-obstructive coronary arteries and normal ejection fraction显示文摘AIM To assess the arrhythmic determinants and prognosis of patients presenting with myocardial infarction and nonobstructive coronary arteries(MINOCA)with normal ejection fraction(EF).METHODS This is an observational analysis of 131 MINOCA patients with normal EF.Three cardiac magnetic resonance(CMR)diagnosis classes were recognized according to the late gadolinium enhancement(LGE)pattern:Myocardial infarction(MI)(n=34),myocarditis(n=47),and'no LGE'(n=50).Ventricular events occurring during hospitalization were recorded and the entire population was followed-up at 1 year.RESULTS Ventricular arrhythmia was observed in 18(13.8%)patients during hospitalization.The'no LGE'patients experienced fewer ventricular events than the MI and myocarditis patients[4.0%vs 26.5%and 14.9%,respectively(P=0.013)].There was no significant difference between the MI and myocarditis groups.On multivariate analysis,LGE transmural extent[OR=1.52(1.08-2.15),P=0.017]and ST-segment elevation[OR=4.65(1.61-13.40),P=0.004]were independent predictors of ventricular arrhythmic events,irrespective of the diagnosis class.Finally,no patient experienced sudden cardiac death or ventricular arrhythmia recurrence at 1-year.CONCLUSION MINOCA patients with normal EF presented no 1-year cardiovascular events,irrespective of the CMR diagnosis class.LGE transmural extent and ST segment elevation at admission are risk markers of ventricular arrhythmia during hospitalization. | Loic Bière Marjorie Niro Hervé Pouliquen Jean-Baptiste Gourraud Fabrice Prunier Alain Furber Vincent Probst | 2017 | World Journal of Cardiology2017，9，3： | 3 |
| 3 | Hepatitis delta virus: From infection to new therapeutic strategies显示文摘The hepatitis delta virus(HDV)is a small RNA virus that encodes a single protein and which requires the hepatitis B virus(HBV)-encoded hepatitis B surface antigen(HBsAg)for its assembly and transmission.HBV/HDV co-infections exist worldwide and show a higher prevalence among selected groups of HBV-infected populations,specifically intravenous drug users,practitioners of high-risk sexual behaviours,and patients with cirrhosis and hepatocellular carcinoma.The chronic form of HDV-related hepatitis is usually severe and rapidly progressive.Patterns of the viral infection itself,including the status of co-infection or super-infection,virus genotypes(both for HBV and HDV),and persistence of the virus’replication,influence the outcome of the accompanying and manifested liver disease.Unfortunately,disease severity is burdened by the lack of an effective cure for either virus type.For decades,the main treatment option has been interferon,administered as mono-therapy or in combination with nucleos(t)ide analogues.While its efficacy has been reported for different doses,durations and courses,only a minority of patients achieve a sustained response,which is the foundation of eventual improvement in related liver fibrosis.The need for an efficient therapeutic alternative remains.Research efforts towards this end have led to new treatment options that target specific steps in the HDV life cycle;the most promising among these are myrcludex B,which inhibits virus entry into hepatocytes,lonafarnib,which inhibits farnesylation of the viral-encoded LHDAg large hepatitis D antigen,and REP-2139,which interferes with HBsAg release and assembly. | Grazia A Niro Arianna Ferro Francesca Cicerchia Isabella Brascugli Marilena Durazzo | 2021 | World Journal of Gastroenterology2021，27，24： | 2 |
| 4 | Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report显示文摘BACKGROUND Cardiac tumors are rare and complex entities.Surgery represents the cornerstone of therapy,while the role of adjuvant treatment remains unclear and,in case of relapse or metastatic disease,the prognosis is very poor.Lack of prospective,randomized clinical trials hinders the generation of high level evidence for the optimal diagnostic workup and multimodal treatment of cardiac sarcomas.Herein,we describe the multidisciplinary clinical management and molecular characterization of a rare case of cardiac myxofibrosarcoma in an elderly woman.CASE SUMMARY A 73-year-old woman presented signs and symptoms of acute left-sided heart failure.Imaging examination revealed a large,left atrial mass.With suspicion of a myxoma,she underwent surgery,and symptoms were promptly relieved.Histology showed a cardiac myxofibrosarcoma,a rare histotype of cardiac sarcoma.Eight months later,disease unfortunately relapsed,and after a multidisciplinary discussion,a chemotherapy with doxorubicin and then gemcitabine was started,achieving partial radiologic and complete metabolic response,which was maintained up to 2 years and is still present.This report is focused on the entire clinical path of our patient from diagnosis to follow-up,through surgery and strategies adopted at relapse.Moreover,due to their rarity,very little is known about the molecular landscape of myxofibrosarcomas.Thus,we also performed and described preliminary genome analysis of the tumor tissue to get further insight on mechanisms involved in tumor growth,and to possibly unveil new clinically actionable targets.CONCLUSION We report a case of cardiac myxofibrosarcoma that achieved a very good prognosis due to an integrated surgical,cardiac and oncologic treatment strategy. | Maristella Saponara Valentina Indio Carmine Pizzi Elena-Daniela Serban Milena Urbini Annalisa Astolfi Pasquale Paolisso Sofia Martin Suarez Margherita Nannini Davide Pacini Valentina Agostini Ornella Leone Valentina Ambrosini Giuseppe Tarantino Stefano Fanti Fabio Niro Francesco Buia Domenico Attinà Maria Abbondanza Pantaleo | 2019 | World Journal of Clinical Cases2019，7，19： | 2 |
| 5 | Comparison of perioperative parameters in one-handed rotational phacoemulsification versus conventional phacoemulsification and femtosecond laser-assisted cataract surgery显示文摘AIM:To compare perioperative parameters of one-handed rotational phacoemulsification technique(one-handed phaco-roll)with each of other two techniques,“Divide et Conquer”and femtosecond laser-assisted cataract surgery(FLACS)METHODS:In this retrospective and comparative cohort study,eyes with uncomplicated cataract(nuclear density grade 2 to 3)treated routinely with one-handed phacoroll(n=23;Group 1)or“Divide et Conquer”(n=23;Group 2)or FLACS(n=23;Group 3)were enrolled.Intraoperative parameters including effective phaco-time(EPt),ultrasound time(USt),aspiration time,surgical time,phacoemulsification(phaco)-power,balanced salt solution(BSS)use,cumulative dissipated energy(CDE)were recorded and compared.Clinical outcomes including best corrected visual acuity(BCVA),corneal endothelial cell density(ECD),endothelial cell loss(ECL),central corneal thickness(CCT)and central macular thickness(CMT),were assessed and compared pre-operatively and at 1mo after surgery.RESULTS:Aspiration and surgical time,and BSS used were lower in Group 1(P<0.01)than other groups.EPt,phaco-power and CDE were lower in Group 1(P<0.05)than Group 2 but not significantly different from Group 3.In Group 1,USt was lower(P<0.05)than Group 2 but higher(P<0.05)than Group 3.BCVA improved in all groups without significant difference between Group 1 and the other ones.No significant differences regarding all post-operative morphologic outcomes(ECD,ECL,CCT,CMT)were reported.No clinical complications occurred.CONCLUSION:One-handed phaco-roll seems to be less time-consuming than“Divide et Conquer”and FLACS and less energy-consuming than“Divide et Conquer”.Furthermore,one-handed phaco-roll seems to have an equal safety profile compared to the other two techniques. | Samuele Gigliola Giancarlo Sborgia Alfredo Niro Carmela Palmisano Pasquale Puzo Gianluigi Giuliani Luigi Sborgia Dario Sisto Valentina Pastore Claudio Furino Rossella Donghia Alessandra Sborgia Francesco Boscia Giovanni Alessio | 2021 | International Journal of Ophthalmology(English edition)2021，14，12： | 2 |
| 6 | High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions 显示文摘 | Di Niro R Mesin L Zheng NY | 2012 | Nature medicine2012，18，3： | 1 |
| 7 | Plasma adiponectin levels in primary biliary cirrhosis:A novel perspective for link between hypercholesterolemia and protection against atherosclerosis显示文摘 | Floreani A Variola A Niro G | 2008 | Am J Gastroenterol2008，103，8： | 1 |
| 8 | Outcome of chronic delta hepatitis in Italy: A long-term cohort study显示文摘 | Grazia Anna Niro Antonina Smedile Antonio Massimo Ippolito Alessia Ciancio Rosanna Fontana Antonella Olivero Maria Rosa Valvano Maria Lorena Abate Domenica Gioffreda Gian Paolo Caviglia Mario Rizzetto Angelo Andriulli | 2010 | Journal of Hepatology2010，，5： | 1 |
| 9 | Numerical simulation of snow melting on pavement surface with heat dissipation pipe embedded 显示文摘 | Nagai Niro Miyamoto Shigenobu | 2008 | Transactions of theJapan Society of Mechanical Engineers B2008，74，3： | 1 |
| 10 | Pharmacological treatment can prevent pancreatic injury after ERCP:a meta-analysis显示文摘 | Andruilli A Leandro G Niro G | 2000 | Gastrointest Endosc2000，51，： | 1 |
| 11 | Differential microRNA-34a expression and tumor suppressor func- tion in retinoblastoma cells显示文摘 | Dalgard CL Gonzalez M de Niro JE | 2009 | Invest Ophthalmol Vis Sci2009，50，： | 1 |
| 12 | Management of symptomatic fibroids:role of supracervical hysterectomy and laparoscopy显示文摘 | Niro J Panel P | 2011 | J Gynecol Ob- stet Biol Reprod (Paris)2011，40，8： | 1 |
| 13 | Stable carbon isotope variability in the seagrass Posidonia oeeaniea: evidence for light intensity effects 显示文摘 | Cooper L W De Niro M J | 1989 | Marine Ecology Progress Services1989，50，3： | 1 |
| 14 | Change in the carbon balance of tropical forests:evidence from long- term plot显示文摘 | Oliver L P Yadrinder M Niro H | 1998 | Science1998，282，： | 1 |
| 15 | Phamacologic treatment can prevent pancreatic injury after ERCP显示文摘 | Andrulli A Leandro G Niro G | 2000 | A meta- analysis Gastrointest Endosco2000，51，： | 1 |
| 16 | Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis显示文摘 | Angelo Andriulli Gioacchino Leandro Grazia Niro Alessandra Mangia Virginia Festa Giovanni Gambassi Maria Rosaria Villani Domenico Facciorusso Pasquale Conoscitore Fulvio Spirito Giovanni De Maio | 2000 | Gastrointestinal Endoscopy2000，，1： | 1 |
| 17 | Pharmacologic treatment can prevent pancreatic injury after ERCP:a meta-analysis显示文摘 | Andriulli A Leandro G Niro G at al | 2000 | Gastrointest Endosc2000，51，1： | 1 |
| 18 | HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years显示文摘 | Massimo Fasano Pietro Lampertico Alfredo Marzano Vito Di Marco Grazia Anna Niro Giuseppina Brancaccio Andrea Marengo Gaetano Scotto Maurizia Rossana Brunetto Giovanni Battista Gaeta Mario Rizzetto Gioacchino Angarano Teresa Santantonio | 2012 | Journal of Hepatology2012，，6： | 1 |
| 19 | Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis 显示文摘 | Floreani A Variola A Niro G Premoli A Baldo V Gambino R | 2008 | Am J Gastroenterol2008，103，： | 1 |
| 20 | Pharmacologic treatment can prevent pancreatic injury after ERCP:a meta analysis显示文摘 | Andriulli A Leandro G Niro G | 2000 | Gastrointest Endosc2000，51，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员